ArticleInternational journal of environmental research and public health2026
Economic Impact of Asbestos in Colombia: Estimation of the Direct and Societal Costs of Lung Cancer and Mesothelioma in 2022.
Article in International journal of environmental research and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asbestos exposure remains an important cause of lung cancer and mesothelioma worldwide, and the long latency of asbestos-related diseases means that health and economic consequences persist even after asbestos bans. In Colombia, the economic burden attributable to historical asbestos exposure has not been comprehensively quantified. This study estimated the economic burden attributable to asbestos exposure in Colombia in 2022 using a prevalence-based cost-of-illness framework from a societal perspective. Direct medical costs were derived from a national lung cancer cost study and updated to 2022 values. Epidemiological inputs were obtained from the Global Burden of Disease (GBD) database. Mesothelioma was considered predominantly attributable to asbestos exposure, while lung cancer was adjusted using population-attributable fractions and an alternative 1:3 mesothelioma-to-lung-cancer ratio scenario. Indirect costs were estimated using the human capital approach, and disability-adjusted life year (DALY) losses were monetized using alternative willingness-to-pay thresholds. Colombia was estimated to have 150 prevalent mesothelioma cases and between 389 and 450 asbestos-attributable lung cancer cases in 2022. Direct costs ranged from USD 6.5 to 10.7 million annually, increasing to USD 16.7-23.1 million when productivity losses were included. Expanded societal valuation scenarios ranged from USD 71 million to more than USD 180 million annually. Asbestos-related malignancies continue to impose a substantial economic burden in Colombia and support the need for strengthened surveillance, long-term management of installed asbestos, and policies aimed at reducing future asbestos-related disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.